Acute Coronary Syndrome, Coronary Disease, Myocardial Infarction
Conditions
Brief summary
The purpose of this study is to compare the antinflammatory and endothelial progenitor cell (EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute coronary syndrome
Interventions
DRUGTELMISARTAN
80 mg daily
DRUGRAMIPRIL
5 mg daily
Sponsors
Catholic University of the Sacred Heart
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Biochemical evidence of myocardial infarction as indicated by elevation of cTnT, * presence of ECG ischemic changes, * angiographic evidence of a primary coronary event, such as plaque erosion and/or rupture, fissuring, or dissection at coronary angiography, * successful coronary revascularization of at least one culprit coronary vessel.
Exclusion criteria
* Age\>80 years, current ACE inhibitor or ARB treatment, * ejection fraction \<35%, infarction secondary to ischemia due to an imbalance of O2 supply and demand, * ECG abnormalities that could affect the recognition of ST segment shift, * recent or chronic infective or inflammatory diseases, * malignancy, and myocardial infarction, * surgery or trauma in the previous month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| High sensitivity C-Reactive Protein | 20 days after hospital discharge |
Secondary
| Measure | Time frame |
|---|---|
| Endothelial Progenitor Cells | 20 days after hospital discharge |
Countries
Italy
Contacts
Primary ContactItalo Porto, MD, PhD
Backup ContactItalo Porto, MD, PhD
Outcome results
None listed